GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine

GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic. The two companies said they planned to work jointly to develop a shot next year that could address “multiple emerging variants in one vaccine”. GSK, the UK’s second biggest pharmaceutical firm and the world’s biggest vaccine maker, will also support the manufacture of up to 100m doses of CureVac’s first-generation Covid-19 vaccine candidate, CVnCoV, this year.